Drug intelligence / Profile preview

Evernia prunastri acetonitrile extract

Development stage: Preclinical
Modality: Small Molecules

Overview

*Evernia prunastri* acetonitrile extract is an experimental phytochemical preparation derived from the lichen *Evernia prunastri*, commonly known as oakmoss. The extract is characterized by its high content of secondary metabolites, specifically evernic acid and usnic acid. Research has demonstrated its potential as an antimicrobial agent against pathogens like *Staphylococcus aureus* and *Candida albicans*. Furthermore, it is being investigated in academic settings as a chemosensitizing adjuvant to enhance the efficacy of standard chemotherapeutic agents such as temozolomide and paclitaxel in treating glioblastoma and breast cancer, potentially through the modulation of the Wnt signaling pathway.

Other names: oakmoss acetonitrile extractEvernia prunastri extract

Beyond the preview

Go deeper on Evernia prunastri acetonitrile extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evernia prunastri acetonitrile extract.

Explore the full profile